Neurocrine Biosciences, Inc.
NBIX
$155.80
$5.213.46%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 814.50M | 805.50M | 794.90M | 687.50M | 572.60M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 814.50M | 805.50M | 794.90M | 687.50M | 572.60M |
| Cost of Revenue | 310.00M | 275.80M | 264.00M | 255.60M | 272.40M |
| Gross Profit | 504.50M | 529.70M | 530.90M | 431.90M | 300.20M |
| SG&A Expenses | 318.50M | 302.50M | 291.60M | 286.30M | 276.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 628.50M | 578.30M | 555.60M | 541.90M | 548.90M |
| Operating Income | 186.00M | 227.20M | 239.30M | 145.60M | 23.70M |
| Income Before Tax | 246.80M | 239.40M | 291.80M | 159.50M | 14.70M |
| Income Tax Expenses | 48.90M | 85.70M | 82.30M | 52.00M | 6.80M |
| Earnings from Continuing Operations | 197.90M | 153.70M | 209.50M | 107.50M | 7.90M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 197.90M | 153.70M | 209.50M | 107.50M | 7.90M |
| EBIT | 186.00M | 227.20M | 239.30M | 145.60M | 23.70M |
| EBITDA | 193.30M | 234.70M | 247.00M | 152.90M | 31.30M |
| EPS Basic | 1.97 | 1.54 | 2.11 | 1.09 | 0.08 |
| Normalized Basic EPS | 1.33 | 1.58 | 1.64 | 1.05 | 0.28 |
| EPS Diluted | 1.91 | 1.48 | 2.04 | 1.06 | 0.08 |
| Normalized Diluted EPS | 1.29 | 1.52 | 1.59 | 1.03 | 0.28 |
| Average Basic Shares Outstanding | 100.50M | 99.90M | 99.40M | 99.00M | 99.70M |
| Average Diluted Shares Outstanding | 103.40M | 103.70M | 102.50M | 101.00M | 102.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |